ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics insider Matsuda Masaru sells 3,674 shares at $25 each—steady 10‑b‑5‑1 trades signal routine liquidity, not distress.

Arcutis insiders buy shares amid 2026 biotech rally, signaling confidence in its immune‑mediated pipeline and upcoming payer deals.

Arcutis Biotherapeutics insider sale shows routine liquidity planning, not a warning. Explore the company’s robust pipeline, strong fundamentals, and market outlook for informed investing.

Arcutis Biotherapeutics insider sale shows routine RSU tax‑withholding, not a sell‑off, while the company’s robust SLE drug, IL‑6 pipeline, and $3.33 B market cap keep investor sentiment positive.

Arcutis insider buys reveal confidence: Welgus Howard G. adds 5,900 shares at $6.52‑$8.63 while selling at $26.18, amid breakthrough approvals and strong Phase II data.

Patrick Burnett’s recent $3.64 insider buy at Arcutis Biotherapeutics signals a discounted opportunity, underscoring confidence in its therapeutic pipeline and potential upside.

ARCUTIS Biotherapeutics insider sale: CEO Todd Watanabe sells 4,375 shares at $26.12 – routine tax move, not a warning, with strong pipeline confidence.

Arcutis Biotherapeutics sees strategic shift with Christopher Peetz’s board appointment and insider buying, hinting at accelerated product launches and Q2 earnings impact.

Arcutis insider buying shows board confidence in its high‑growth biotech pipeline, yet investors should watch upcoming trials and regulatory milestones for real value.

Arcutis Biotherapeutics insider sale